Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma

Am J Ophthalmol. 2006 Oct;142(4):673-5. doi: 10.1016/j.ajo.2006.05.003.


Purpose: To determine the efficiency of topical cyclosporine-A (CSA) combined with mitomycin C (MMC) as an adjunctive treatment in diffuse conjunctival and corneal squamous cell carcinoma (CCSC).

Design: Interventional case reports.

Methods: Two patients who had positive margins following surgical excision of CCSC were treated by topical CSA (0.05%) four times a day for 12 weeks, and topical MMC (0.01%) four times a day was combined with CSA at the second, fourth, and sixth weeks of the treatment. We controlled the tumor recurrence, vision, and ocular surface healing during the follow-up.

Results: There was no tumor recurrence during the follow up of 18 months. Limbal vascularization regressed considerably and the vision improved without any ocular surface problems in both patients.

Conclusions: As an adjunctive treatment, topical CSA (0.05%) combined with MMC (0.01%), may prevent tumor recurrence and provide excellent ocular surface healing in diffuse CCSC.

Publication types

  • Case Reports

MeSH terms

  • Administration, Topical
  • Aged
  • Antibiotics, Antineoplastic / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Conjunctival Neoplasms / drug therapy*
  • Conjunctival Neoplasms / pathology
  • Corneal Diseases / drug therapy*
  • Corneal Diseases / pathology
  • Cyclosporine / therapeutic use*
  • Drug Therapy, Combination
  • Eye Neoplasms / drug therapy*
  • Eye Neoplasms / pathology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Mitomycin / therapeutic use*


  • Antibiotics, Antineoplastic
  • Immunosuppressive Agents
  • Mitomycin
  • Cyclosporine